Popular Keywords
Human Retroviruses
Virus Replication
Viral Pathogenesis
HIV prevention science
Vaccine research
Co infections
Correspondence to Author: Ganokwan Hongsaengdao
, Department of Medicine, College of Medicine, Rangsit University Bangkok, Thailand.
Abstract:
Infection of the central nervous system (CNS) by the human herpes virus (HHV) is a widespread issue throughout the world. At Rajavithi Hospital in Bangkok, Thailand, researchers have examined the prevalence
of HHV-CNS infection in both HIV/AIDS patients and non-HIV patients.
To determine the frequency and incidence of HHV1 (HSV), HHV3 (VZV),
HHV4 (EBV), HHV5 (CMV), HHV6A,B, and HHV 7-CNS infection in patients
at Rajavithi Hospital in Bangkok, Thailand, as well as to distinguish between HSV-encephalitis and non-HSV/HHV-CNS infection based on clinical manifestations and laboratory results. Patients with a clinically suspected CNS infection were included in an 18-month prospective trial.
Examination and culture of the cerebrospinal fluid (CSF) were carried
out, as well as real-time polymerase chain reaction (RT-PCR) testing for
Mycobacterium tuberculosis, HSV-1, HHV3, HHV4, HHV5, HHV6, and
HHV7.
The presence of fever, headache, seizures, altered consciousness, neurological localising symptoms, and/or stiff neck were necessary for the
diagnosis of HHV-CNS infection. Between July 2008 and December 2009,
94 patients (mean + SD = 42.3 + 14.5 years) with 52 male and 42 female
participants were enrolled. The patients ranged in age from 16 to 77
years. It was determined that 44 patients tested positive for HIV/AIDS.
Twenty-seven percent of them received highly active antiretroviral therapy (HAART). Age and gender differences were statistically significant (p
< 0.026) between the HIV/AIDS and non-HIV subgroups. 11.3% of cases of HHV encephalitis occurred annually. The annual incidence of latent
infection caused by HHV5 (CMV), HHV4 (EBV) encephalitis, and HHV1
(HSV) viral encephalitis was 5.67, 4.2, and 0.6%, respectively. No signs
of HHV6A, B, or HHV7-related CNS infections were found. HIV/AIDS patients had a significantly increased prevalence of HHV encephalitis (p
= 0.002). Compared to patients without HSV/HHV-CNS infection, those
with HSV1 encephalitis had a higher CSF/blood sugar ratio (p = 0.06).
It has been discovered that human herpes virus, particularly HSV-CNS
infection, is prevalent in both HIV/AIDS and non-HIV patients. VZV, EBV,
HHV6, and HHV7-related CNS infections were uncommon. In contrast to
the CSF/blood sugar ratio and CSF pleocytosis, clinical signs might not
be useful in distinguishing between non-HSV/HHV-CNS infection and
HSV encephalitis.
Keywords: : Human herpes virus (HHV), central nervous system (CNS) infection, human immunodeficiency virus (HIV), viral encephalitis, herpes simplex virus (HSV), varicella zoster virus (VZV), Ebstein barr virus (EBV).
INTRODUCTION
Central nervous system (CNS) infection by the human herpes
virus (HHV) is a widespread issue that can have serious consequences if therapy is not received (Boriskin et al., 2004). Thus
far, there have been few reports of HHV-CNS infection in HIV/
AIDS and non-HIV patients in Thailand (Subsai et al., 2004, 2006;
Windy et al., 2008). HHV1 (Herpes simplex virus, or HSV) and
HHV3-CNS infection were reported to be 15.3 and 5.8%, respectively, in a study conducted in the USA (New York). CMV, EBV,
and HHV-6 infections are more common causes of encephalitis
in immunocompromised hosts. In 2001 and 2002, the incidence
rate of HHV5-CNS infection in AIDS cases with documentation
was reported to be 7 per 100 person-years at Chiang Mai University Hospital in Thailand.
The following symptoms can be used to make a clinical diagnosis of HHV-CNS infection:
1) fever, headache, seizure, altered consciousness, neurological
localising sign, and/or stiff neck;
2) lumbar puncture performing CSF lymphocytic pleocytosis,
with the possible exception of HHV5 (CMV) - CNS infection,
which may have neutrophilic pleocytosis;
3) increased CSF protein6; and
4) Polymerase chain reaction positivity for HHV DNA (Table 5).
The purpose of this study was to determine the prevalence and
incidence of HHV1 (HSV), HHV3 (VZV), HHV4 (EBV), HHV5 (CMV),
HHV6A, B, and HHV 7-CNS infection at Rajavithi Hospital in
Bangkok, Thailand. Additionally, the study aimed to distinguish
between HSV-encephalitis and non-HSV/HHV-CNS infection
based on laboratory findings and clinical manifestations.
Patients and methods
Patients with a clinically suspected CNS infection were included
in an 18-month prospective trial. Examination and culture of cerebrospinal fluid (CSF) were carried out, as well as polymerase
chain reaction (PCR) testing for Mycobacterium tuberculosis,
HSV-1, HHV3, HHV4, HHV5, HHV6, and HHV7. Fever, headache,
seizures, altered awareness, and neurological localising signals
+/- stiff neck were required for the diagnosis of HHV-CNS infection. Enrolled were patients over the age of 15, suspected
of having a CNS infection without a lumbar puncture contraindication, capable of giving informed consent on their own or
through a family member, and able to undergo the procedure.
Individuals who were deemed to have a severe pathogenic viral
infection, such as SARS or bird flu (H5N1), were not allowed to
participate in this study.
Complete blood count (CBC), anti-HIV test results, and CD4
counts were documented in clinical laboratory data. Primers
specific sequences for HSV-1, HHV3, HHV4, HHV5, HHV6, and
HHV7 were used in the Sybergreen ®-Roche® real-time polymerase chain reaction (RT-PCR) in 20 µl. These sequences were
designed to target specific viral strains based on a comprehensive search of the GenBank database (www.ncbi.nlm.nih.gov)
(Boriskin et al., 2004) (Table 1), with sensitivity of 93 and specificity of 100. There was a 100% positive predictive value and an
83% negative predictive value. There was also use of Mycobacterium tuberculosis. 200 µl of CSF total, taken from patients suspected of having a CNS infection, was subjected to automated
DNA extraction using the Roche MagNa pure Compact Nucleic
and Isolation Kit.
RESULTS
Between July 2008 and December 2009, a total of 94 patients—52 men and 42 women—between the ages of 16 and 77
(Mean + SD = 42.3 + 14.5) were included. Of the 44 individuals
whose HIV status was confirmed, 27 percent received highly active antiretroviral therapy (HAART). Age and gender differences
were statistically significant (p < 0.026) between the HIV/AIDS
and non-HIV subgroups. Table 2 provides specific demographic information. 141 CSF samples in all were taken during the
enrollment phase 29 individuals were diagnosed with non-CNS
infections, while 65 patients had a conclusive CNS infection.
Clinical features of individuals who may have a central nervous
system infection. Meningitis caused by tuberculous meningitis
is a non-HHV CNS infection.
11.3% of cases of HHV encephalitis occurred annually. HHV1
viral encephalitis, HHV5 (CMV) latent infection, and HHV4 encephalitis had annual incidence rates of 5.67, 4.2, and 0.6%,
respectively. The group that was enrolled did not exhibit any
CNS infections caused by HHV6A, B, or HHV7. The frequency of
HHV 16 patients had HHV-CNS infection, 8 had HSV-1 infection,
6 had latent CMV infection, 1 had VZV infection, and 1 had EBV
encephalitis.
DISCUSSION
According to this study, HSV was the most frequent source of
HHV-CNS infection (11.3%), particularly in those who were HIV
positive (62.5%) as opposed to those who were not (37.5%).
Rajavithi Hospital’s HHV-related CNS infection prevalence was
the same as that reported in other parts of the world (Laser et
al., 2003). (Ali et al., 2005; Behnam et al., 2007; Mendoza et al.,
2007). Comparing this prospective study to the USA (New York)
study revealed a somewhat reduced prevalence of HHV-CNS infection.
Additionally, HHV-related CNS infection was shown to be significantly more common in HIV-positive patients (p = 0.002), according to this study. In contrast, HHV6 and HHV7 CNS infection
was not found in our enrolled adult group in a prior publication
of encephalitis in Thai children. Furthermore, HHV-related CNS
infection was much more common in HIV-positive patients, according to our research (p = 0.002).
When compared to non-HSV/HHV - CNS infection, we did not
discover seizure to be a predictive hint for HSV encephalitis,
which is in contrast to a German encephalitis study (Ali et al.,2005). In environments with limited resources and infrequent
access to RT-PCR, the CSF/blood sugar ratio in cases with HSV
encephalitis appeared to be greater than that of non-HSV/HHV
CNS infection (p = 0.06). It’s possible that a non-HSV/HHV CNS
infection is the cause of the CSF pleocytosis (> 200 cells/mm 3)
(p=0.19) (Table 7). But in environments with limited resources,
it is necessary to screen out other prevalent CNS infections before making the diagnosis of HHV-related CNS infection.
For up to two thirds of HIV-positive patients, routine intravenous
Acyclovir treatment may be helpful when encephalitis is suspected. In contrast, intravenous Acyclovir treatment may not be
beneficial for HIV-positive individuals with low CSF/blood sugar ratios (20%) and CSF pleocytosis more than 200 cells/mm3,
as the most likely cause was determined to be a CNS infection
rather than HSV/HHV. It was discovered that CMV encephalitis
was uncommon and that retinitis was the most frequent sign of
CMV infection in HIV patients (Chokephaibulkit et al., 2001). We
only discovered CMV latent infection in this investigation. The
diagnosis of individuals with neurological immune restoration
syndrome may also benefit from CSF study, which includes culture, RT-PCR for HHV DNA detection, and RT-PCR TB.
The small sample size, lack of CSF positive controls for HHV2, and lack of testing for CNS ribonucleic acid (RNA) viral infections were the limitations of our investigation. Future research should focus on developing multiplex RT-PCR with hybridization probes, as this will provide higher sensitivity and diagnosis confirmation.
Conclusions
At Rajavithi Hospital in Thailand, human herpes virus infections, particularly HSV-CNS infection, were prevalent in both
HIV-positive and non-HIV patients. Although CSF/blood sugar
ratio (p=0.06) and CSF pleocytosis (p=0.19) were helpful in this
study in differentiating between HSV-encephalitis and non-HSV/
HHV - CNS infection, they may not be as useful in other contexts
where HSV/HHV - CNS infection may be a factor.
REFERENCES
1. Ali II, Michel TO, Muhidien JJ (2005) Prevalence of Herpes
Simplex Virus, Varicella-Zoster Virus, Cytomegalovirus,
and Human Herpesvirus 6 and 7 DNA in cerebrospinal Fluid of Middle Eastern Patients with Encephalitis, J. Clin.
Microbiol. 43: 4172-4174.
2. Behnam S, Mohammad M, Nima Z (2007). Viral infection,
prevalence and costs: A 5-year, hospital based,retrospective observational study in Shiraz,Iran. Pakistan J. Med.
Sci. 26: 580-584.
3. Boriskin YS, Rice PS, Stabler RA (2004). DNA Microarrays
for Virus Detection in case of Central Nervous System Infection. J. Clin. Microbiol. 42(12): 5811-5818.
4. Chokephaibulkit KK, Apitanapong PS (2001). Pediatr. Infect. Dis. J. 20(2): 216-218.
5. Huang C, Chatterjee NK, Grady LJ (1999). Diagnosis of viral infections of the central nervous system. New Engl . J.
Med. 340: 483.
6. Laser G, Gilliam CA, Schnurr S (2003). In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998-2000. Clin. Infect. Dis. 36: 731.
7. Mendoza LP, Bronzoni RV, Takayanagui OM (2007). Viral
infection of the central nervous system in Brazil, J. Infect.
54(6): 589-596.
8. Subsai K, Kanoksri S, Siwaporn C, Helen L (2004). Eur. J.
Neurol. 11: 755-759.
9. Subsai K, Kanoksri S, Siwaporn C, Helen L (2006). Eur. J.
Neurol. 13: 233-239.
10. Windy C, John J (2008). Update in the Diagnosis and management of Central Nervous System Infections, Neurol.
Clin. 26: 427-468
Citation:
Ganokwan Hongsaengdao. Aids and non-Aids people who have a cerebral infection caused by the human viral disease herpes. Journal of HIV/AIDS Research 2024.
Journal Info
- Journal Name: Journal of HIV/AIDS Research
- Impact Factor: 1.4**
- ISSN: 2996-1629
- DOI: 10.52338/Johr
- Short Name: JOHR
- Acceptance rate: 55%
- Volume: (2024)
- Submission to acceptance: 25 days
- Acceptance to publication: 10 days
OUR PUBLICATION BENEFITS
- International Reach
- Peer Review
- Rapid Publication
- Open Access
- High Visibility